Company’s 36-month beta value is 1.25.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PYPD is 6.66M, and currently, short sellers hold a 0.52% ratio of that floaft. The average trading volume of PYPD on June 19, 2025 was 428.03K shares.
PYPD) stock’s latest price update
Polypid Ltd (NASDAQ: PYPD)’s stock price has decreased by -6.23 compared to its previous closing price of 3.53. However, the company has seen a -4.34% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid’s runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.
PYPD’s Market Performance
Polypid Ltd (PYPD) has seen a -4.34% fall in stock performance for the week, with a 17.79% gain in the past month and a 14.53% surge in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are at 4.84% for PYPD. The simple moving average for the last 20 days is 6.37% for PYPD stock, with a simple moving average of 6.85% for the last 200 days.
Analysts’ Opinion of PYPD
Many brokerage firms have already submitted their reports for PYPD stocks, with Roth Capital repeating the rating for PYPD by listing it as a “Buy.” The predicted price for PYPD in the upcoming period, according to Roth Capital is $9 based on the research report published on June 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PYPD reach a price target of $11. The rating they have provided for PYPD stocks is “Buy” according to the report published on June 02nd, 2025.
Rodman & Renshaw gave a rating of “Buy” to PYPD, setting the target price at $13 in the report published on January 28th of the current year.
PYPD Trading at 15.35% from the 50-Day Moving Average
After a stumble in the market that brought PYPD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.28% of loss for the given period.
Stock Fundamentals for PYPD
The total capital return value is set at -2.24. Equity return is now at value -853.05, with -146.02 for asset returns.
The debt to equity ratio resting at 1.25. The interest coverage ratio of the stock is -29.47.
Currently, EBITDA for the company is -25.83 million with net debt to EBITDA at 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
In a nutshell, Polypid Ltd (PYPD) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
